目的: 分析医药购销领域存在的突出秩序问题,系统评估医药价格和招采信用评价制度的实施成效,并提出优化对策。方法: 基于政策文本分析、官方统计数据及典型案例,结合2020年制度建立至2025年修订完善的实践历程,采用问题—对策—成效的逻辑框架进行系统分析。结果: 医药购销市场存在带金销售、虚开发票、围标串标等交易乱象,价格机制失灵导致申报价格虚高、恶性竞争循环及失信成本偏低,传统监管方式滞后且跨部门信息共享不畅。信用评价制度通过规范交易全流程、强化数据协同、收紧评价标准、坚持处置与引导并重、维护企业合法权益等五方面机制,有效遏制了违规行为。截至2026年1月,全国现存评定失信企业1236家,公开通报10余起典型案例,多数失信企业通过降价、退回不合理收益等方式完成信用修复。结论: 医药价格和招采信用评价制度是规范购销秩序、提升监管效能的有效政策工具,未来应进一步细化评价标准、深化跨部门协同、推动信用评价结果在更多场景应用。

Objective: The paper analyzes the prominent problems in the order of pharmaceutical procurement, systematically evaluates the implementation effectiveness of the credit evaluation system of pharmaceutical pricing, bidding and procurement, and proposes optimization strategies. Methods: Based on policy text analysis, official statistical data, and typical cases, combined with the practical experience from the system’s establishment in 2020 to its revision and improvement in 2025, a systematic analysis was conducted using a problem-countermeasure-effectiveness logical framework. Results: The pharmaceutical procurement market faces transactional chaos, such as kickback sales, false invoicing, and bid-rigging. Price mechanism failures lead to inflated declared prices, vicious competition cycles, and low default costs. Traditional regulatory methods lag behind, and cross-departmental information sharing is inadequate. The credit evaluation system has effectively curbed violations through five mechanisms: standardizing the entire transaction process, strengthening data collaboration, tightening evaluation criteria, balancing punishment with guidance, and protecting enterprises’ legitimate rights and interests. As of January 2026, a total of 1236 enterprises have been assessed as enterprises with credit violations nationwide, more than 10 typical cases have been publicly notified, and most enterprises with credit violations have completed credit restoration by reducing prices or returning unreasonable profits. Conclusion: The credit evaluation system of pharmaceutical pricing, bidding and procurement is an effective policy tool for standardizing the procurement order and enhancing regulatory effectiveness. Future efforts should further refine evaluation criteria, deepen cross-departmental collaboration, and promote the application of credit evaluation results in more scenarios.